FVIII inhibitors were detected much more frequently in severe hemophilia patients (16/72, 22%) as compared to moderately affected peers (5/48, 10%), but the difference in proportion did not reach statistical significance as shown in Table 2. This evidence concerns the gene F8 and hemophilia.